[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100453690":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":30,"locations":40,"responsibleParty":63,"collaborators":65,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":25,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":25,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":43,"whyStopped":25,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Helse Stavanger HF","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with positive blood test for biomarkers for Alzheimer's disease","EXPERIMENTAL","The positive blood tests results for this group will be compared with the results from the investigation at the at the memory outpatient clinic to calculate the number of false positive blood tests (using the results from the outpatient clinic as a \"gold standard\" for the diagnosis)",[13],"Diagnostic Test: predictive value of a blood test",{"label":15,"type":16,"description":17,"interventionNames":18},"Patients with negative blood test for biomarkers for Alzheimer's disease","ACTIVE_COMPARATOR","The negative blood tests results for this group will be compared with the results from the investigation at the at the memory outpatient clinic to calculate the number of false negative blood tests (using the results from the outpatient clinic as a \"gold standard\" for the diagnosis)",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIAGNOSTIC_TEST","predictive value of a blood test","Evaluation of the clinical value of a new blood based test for diagnosis of Alzheimer's disease in a general practice population.",[15,9],null,[27],{"name":28,"affiliation":5,"role":29},"Svein Skeie, MD PhD","STUDY_DIRECTOR",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Svein R Kjosavik, MD PhD","CONTACT","+4790414252","svein.kjosavik@sus.no",{"name":37,"role":33,"phone":38,"phoneExt":25,"email":39},"Anita L. Sunde, MD","+4746696494","anita.lenora.sunde@sus.no",[41],{"facility":42,"status":43,"city":44,"state":25,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Stavanger University Hospital","RECRUITING","Stavanger","4068","Norway","NO",{"type":49,"coordinates":50},"Point",[51,52],5.73332,58.97005,{"lat":52,"lon":51},[55,60],{"name":56,"role":33,"phone":57,"phoneExt":58,"email":59},"Anita Sunde, MD","46696494","+47","anitalenora@gmail.com",{"name":61,"role":33,"phone":62,"phoneExt":58,"email":35},"Svein Kjosaviki, MD PhD","90414252",{"type":64,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[66],{"name":67,"class":68},"Sahlgrenska University Hospital","OTHER","100453690","blood-based-biomarkers-for-diagnosis-of-alzheimers-100453690",false,"NCT05187819","Blood-based Biomarkers for Diagnosis of Alzheimer's","Accuracy of Blood-based Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice","Inclusion Criteria:\n\n* Participants suspected by their GP to have possible dementia, based on history, clinical examination and\u002For cognitive screening\n\nExclusion Criteria:\n\n* Lack of capacity for consent as judged by the GP.\n* Severe psychiatric disease, use of medication or physical disease that according to the GP may affect participation or likely contribute significantly to the observed cognitive impairment.\n* Patients not wanting to be referred to the memory outpatient clinic.","ALL","40 Years","100 Years",{"count":80,"type":81},300,"ESTIMATED","INTERVENTIONAL",[84],"NA","Alzheimer's disease (AD) may currently be diagnosed using molecular biomarkers in cerebrospinal fluid (CSF) and\u002For positron emission tomography (PET). These diagnostic procedures are highly accurate, but the high cost and low availability hamper their feasibility. Recently, ultrasensitive blood tests predicting Alzheimer pathologies in the brain have been developed. These tests have a reliable ability to differentiate AD from other neurodegenerative disorders and identify AD across the clinical continuum with high sensitivity and specificity in research cohorts with a high prevalence of AD.\n\nThis project will assess the predictive value of these tests in a general practice population.\n\nThe hypothesis is that the actual blood panel will have high positive predictive value for a diagnosis of Alzheimer's disease in the primary health care setting.",[87],"Dementia Alzheimers",[89,90,91,92],"Alzheimer's dementia","Diagnosis","Biomarkers","Clinical practice","2023-09-26",{"date":95,"type":96},"2023-09-28","ACTUAL",{"date":98,"type":96},"2023-06-01",{"date":100,"type":81},"2029-12-31",{"name":5,"class":6},1]